# DESCRIPTION

## BACKGROUND OF THE DISCLOSURE

- introduce ocular neovascularization
- describe diseases related to ocular neovascularization
- discuss limitations of current treatments
- motivate Ref-1/APE1 as a target
- describe Ref-1/APE1 function
- discuss APX3330 as a Ref-1 inhibitor
- describe APX3330's effects on angiogenesis
- motivate need for second-generation Ref-1 inhibitors
- summarize background

## BRIEF DESCRIPTION

- introduce APX2009 and APX2014
- describe enhanced Ref-1 inhibition
- summarize antiproliferative effects
- describe tube formation inhibition
- summarize ex vivo choroidal sprouting inhibition
- summarize in vivo CNV treatment

## DETAILED DESCRIPTION

- introduce APE1 inhibitors
- describe APE1 protein interaction
- describe APE1 redox signaling function
- introduce APX2009 and APX2014
- describe APE1 inhibitor formula
- describe R1, R3, R4, R5, and R6 groups
- describe X and Y groups
- introduce APX3330 and analogs
- describe APX2009 and APX2014 effects
- describe antiangiogenic effects
- describe transcription factor regulation
- introduce suitable dosages
- describe APX2009 dosage
- describe APX2014 dosage
- introduce pharmaceutically acceptable carriers
- describe composition preparation
- introduce additional therapeutic agents
- describe anti-VEGF therapies
- describe other therapeutic agents
- introduce subject in need
- define technical terms

## EXAMPLES

### Example 1

- introduce APX2009 and APX2014
- describe function on AP-1 DNA binding and cell proliferation and migration
- outline synthetic methods
- describe synthesis of iodolawsone
- describe synthesis of (E)-2-((3-hydroxy-1,4-dioxo-1,4-dihydronaphthal
- describe synthesis of (E)-2-((3-hydroxy-1,4-dioxo-1,4-dihydronaphthal
- describe synthesis of (E)-N,N-diethyl-2-((3-chloro-1,4-dioxo-1,4-d
- describe synthesis of (E)-N-methoxy-2-((3-chloro-1,4-dioxo-1,4-d
- describe synthesis of (E)-N,N-diethyl-2-((3-methoxy-1,4-dioxo-1,4
- describe synthesis of (E)-N-methoxy-2-((3-methoxy-1,4-dioxo-1,4
- describe APX3330 synthesis
- outline electrophoretic mobility shift assays (EMSA)
- describe cell culture
- outline in vitro cell proliferation assay
- describe EdU incorporation, Ki-67 staining, and TUNEL
- outline cell cycle analysis
- describe in vitro cell migration assay
- outline in vitro Matrigel tube formation assay
- describe NF-κB p65 nuclear translocation assay
- outline qRT-PCR
- describe animal experiments
- outline choroidal sprouting experiments
- describe L-CNV experiments
- outline anesthesia and treatment procedures
- describe randomization of treatments
- outline APX2009 and APX2014 effects on AP-1 DNA binding
- describe APX2009 and APX2014 effects on cell proliferation and migration
- outline APX2009 and APX2014 effects on cell cycle
- describe APX2009 and APX2014 effects on NF-κB p65 nuclear translocation
- outline APX2009 and APX2014 effects on gene expression
- describe APX2009 and APX2014 effects on choroidal sprouting and L-CNV
- introduce choroidal sprouting assay
- describe ex vivo choroidal sprouting
- describe laser-induced choroidal neovascularization
- describe in vivo imaging
- describe choroidal flatmount immunofluorescence
- describe statistical analyses
- summarize results
- describe Ref-1 inhibitors APX2009 and APX2014
- describe blocking endothelial cell proliferation
- describe blocking S phase without inducing apoptosis
- describe blocking endothelial cell migration
- describe blocking endothelial cell tube formation
- describe inhibiting NF-κB activity
- describe blocking angiogenesis ex vivo
- describe systemic Ref-1 inhibition with APX3330
- describe systemic administration of APX2009
- discuss redox signaling inhibition
- discuss DNA repair inhibition
- discuss antiangiogenic effects
- discuss transcription factors modulated by Ref-1 inhibition
- discuss toxicity of APX3330 and APX2009
- discuss ocular toxicity and pharmacokinetics
- discuss systemic drug therapy
- discuss advantages of oral bioavailability
- discuss patient and healthcare system costs
- summarize results of Ref-1 inhibitors
- discuss therapeutic utility for wet AMD
- discuss utility for retinal neovascular diseases
- discuss in vitro data
- conclude therapeutic potential of Ref-1 inhibitors

### Example 2

- treat cells with APX2009
- analyze RNA expression
- show Ref-1 regulates NF-κB signaling

### Example 3

- analyze Ref-1 expression in ocular tissues

